EMA recommends revoking marketing authorisation for Amgen's rare-disease drug

The European Medicines Agency recommended revoking Amgen's marketing authorisation for Tavneos, saying the drug's benefits do not outweigh its risks. The decision is a negative regulatory setback for Amgen's rare autoimmune disease treatment and could pressure the stock. While not a sector-wide event, the ruling may materially affect the product's commercial prospects in Europe.

Analysis

The European Medicines Agency recommended revoking Amgen's marketing authorisation for Tavneos, saying the drug's benefits do not outweigh its risks. The decision is a negative regulatory setback for Amgen's rare autoimmune disease treatment and could pressure the stock. While not a sector-wide event, the ruling may materially affect the product's commercial prospects in Europe.